Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.54 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2582420 | 1.00 | HSD11B1 (0.54) | HSD11B1LY96BCHEALDH1A1KMT2A | |
| SCHEMBL265503 | 1.00 | HSD11B1 (0.54) | HSD11B1LY96BCHEALDH1A1KMT2A | |
| SCHEMBL8900317 | 0.84 | HSD11B1 (0.62) | HSD11B1LY96BCHEALDH1A1KMT2A | |
| SCHEMBL1751871 | 0.84 | HSD11B1 (0.62) | HSD11B1LY96BCHEALDH1A1KMT2A | |
| SCHEMBL297691 | 0.84 | HSD11B1 (0.62) | HSD11B1LY96BCHEALDH1A1KMT2A | |
| SCHEMBL31613215 | 0.84 | HSD11B1 (0.62) | HSD11B1LY96BCHEALDH1A1KMT2A | |
| SCHEMBL4214812 | 0.81 | ALDH1A1 (0.37) | HSD11B1LY96ALDH1A1KMT2AMEN1 | |
| SCHEMBL12913343 | 0.81 | ALDH1A1 (0.37) | HSD11B1LY96ALDH1A1KMT2AMEN1 | |
| SCHEMBL21786281 | 0.81 | ALDH1A1 (0.37) | HSD11B1LY96ALDH1A1KMT2AMEN1 | |
| SCHEMBL333121 | 0.81 | NFE2L2 (0.41) | ALDH1A1KMT2AMEN1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0314778-B1 | SUBSTITUTED AROMATIC SILANE COMPOUNDS AND METHOD FOR PREPARATION OF SAME | Hughes Aircraft Company (US) | 1991-06-19 | — | — | EP | claimed |
| US-4861901-A | Substituted aromatic silane compounds and method for preparation of same | HUGHES AIRCRAFT COMPANY (US) | 1989-08-29 | — | — | US | claimed |
| EP-0314778-A1 | SUBSTITUTED AROMATIC SILANE COMPOUNDS AND METHOD FOR PREPARATION OF SAME. | HUGHES AIRCRAFT CO (US) | 1989-05-10 | — | — | EP | claimed |
| US-4788268-A | Method for preparation of epoxysilicone compounds and allyl-terminated silicone compounds | HUGHES AIRCRAFT COMPANY (US) | 1988-11-29 | — | — | US | claimed |
| WO-1988008846-A1 | SUBSTITUTED AROMATIC SILANE COMPOUNDS AND METHOD FOR PREPARATION OF SAME | HUGHES AIRCRAFT COMPANY (US) | 1988-11-17 | — | — | WO | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230077225-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-11453683-B1 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4021444-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-2694491-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012138776-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| EP-0314778-B1 | SUBSTITUTED AROMATIC SILANE COMPOUNDS AND METHOD FOR PREPARATION OF SAME | Hughes Aircraft Company (US) | 1991-06-19 | — | — | EP | disclosed |
| US-4788268-A | Method for preparation of epoxysilicone compounds and allyl-terminated silicone compounds | HUGHES AIRCRAFT COMPANY (US) | 1988-11-29 | — | — | US | disclosed |
| EP-0018144-A1 | A process for the preparation of substituted 2-aminopyrazines | ELI LILLY AND COMPANY (US) | 1980-10-29 | — | — | EP | disclosed |
| EP-0017494-A2 | Hydroxyimino-substituted aminoacetonitrile intermediates and their preparation | ELI LILLY AND COMPANY (US) | 1980-10-15 | — | — | EP | disclosed |
| US-4211870-A | FROM AMINOACETONITRILE AND A PHENYL A-HALO OXIME | ELI LILLY AND COMPANY (US) | 1980-07-08 | — | — | US | disclosed |
| US-4199525-A | Hydroxyimino-substituted aminoacetonitriles | ELI LILLY AND COMPANY (US) | 1980-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | HSD11B1 847/4885LY96 2822/4885BCHE 4329/4885 |
| US-20230077225-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | HSD11B1 790/4885LY96 2830/4885BCHE 4293/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | HSD11B1 865/4885LY96 4100/4885BCHE 4730/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | HSD11B1 596/4885LY96 3895/4885BCHE 4561/4885 |
| US-11453683-B1 | KRas G12D inhibitors | KRAS, NRAS, HRAS | HSD11B1 599/4885LY96 3880/4885BCHE 4577/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | HSD11B1 790/4885LY96 2830/4885BCHE 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.